Arch Therapeutics Inc (ARTH) Analysts See $-0.01 EPS

November 21, 2017 - By Ellis Scott

 Arch Therapeutics Inc (ARTH) Analysts See $ 0.01 EPS

Analysts await Arch Therapeutics Inc (OTCMKTS:ARTH) to report earnings on December, 4. After $-0.01 actual earnings per share reported by Arch Therapeutics Inc for the previous quarter, Wall Street now forecasts 0.00 % EPS growth. About 71,501 shares traded. Arch Therapeutics Inc (OTCMKTS:ARTH) has 0.00% since November 21, 2016 and is . It has underperformed by 16.70% the S&P500.

Arch Therapeutics, Inc. is a development-stage company. The company has market cap of $84.93 million. The Firm operates as a biotechnology company. It currently has negative earnings. The Firm focuses on developing products to stop bleeding and control leaking (sealant) during surgery and trauma care.

More important recent Arch Therapeutics Inc (OTCMKTS:ARTH) news were published by: Seekingalpha.com which released: “Tiny Arch Therapeutics Just Doubled: Time To Dump?” on April 11, 2016, also Seekingalpha.com published article titled: “Can Arch Therapeutics Stop The Bleeding… In Patients, That Is”, Seekingalpha.com published: “Arch Therapeutics Seals The Deal On Strong Trial Data For Its AC5 Hemostatic …” on August 16, 2016. More interesting news about Arch Therapeutics Inc (OTCMKTS:ARTH) was released by: Marketwatch.com and their article: “Arch Therapeutics Inc.” with publication date: July 11, 2013.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.